Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Eosinophilic Esophagitis (MESSINA)
2019-002871-32Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Benralizumab 30 mg Q4W with Placebo (2 arms). Primary endpoint: Dual-primary Endpoints. Started Dec 2019; status: terminated.
02
Drugs
benralizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2019-002871-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002871-32.